September 24, 2020 -- Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.
KNP-301 is designed to treat complement-mediated and angiogenesis-driven retinal diseases by suppressing both complement component 3 (C3b) and vascular endothelial growth factor (VEGF) as a bispecific approach. The therapy is the first biologics program out of Kanaph Therapeutics that is preparing for global clinical trials.
Under the agreement, Samsung Biologics will provide full contract development organization services including cell line development, process development, nonclinical and clinical material manufacturing, and investigational new drug submission.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
